Bret Lashner

Appearances

DURABILITY OF THE CLINICAL RESPONSE TO SER-109, AN INVESTIGATIONAL ORAL MICROBIOME THERAPEUTIC, IN A PHASE 3 OPEN-LABEL TRIAL (ECOSPOR IV) IN PATIENTS WITH RECURRENT <i>CLOSTRIDIOIDES DIFFICILE</i> INFECTION
Date
May 8, 2023
BACKGROUND: Recurrent _Clostridioides difficile _infection (rCDI) is a debilitating disease associated with significant healthcare burden and low quality of life. The greatest risk factor for rCDI is a history of recurrence, although older age (≥65 years) and comorbidities also increase risk…
Speakers
Edward Huang
Bret Lashner
Matthew Sims
Bharat Misra
Huy Tran
Sahil Khanna
Mayo Clinic
Elaine Wang
Ananya De
Kelly Brady
David Lombardi
Asli Memisolglu
Barbara McGovern
Lisa von Moltke
Presenter
Louis Korman